 Cecilia Low Wang
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 10 | 2024 | 2174 | 1.700 |
Why?
| | Hyperglycemia | 4 | 2022 | 312 | 1.560 |
Why?
| | Diabetes Mellitus | 4 | 2021 | 942 | 1.240 |
Why?
| | Lower Extremity | 3 | 2021 | 335 | 1.170 |
Why?
| | Cardiovascular System | 2 | 2019 | 127 | 1.160 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 402 | 1.010 |
Why?
| | Peripheral Arterial Disease | 3 | 2021 | 377 | 0.990 |
Why?
| | Hypoglycemic Agents | 3 | 2022 | 1032 | 0.880 |
Why?
| | Cardiovascular Diseases | 4 | 2024 | 1798 | 0.870 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 387 | 0.760 |
Why?
| | Blood Glucose | 5 | 2024 | 1939 | 0.730 |
Why?
| | Epidemics | 1 | 2021 | 70 | 0.730 |
Why?
| | Drug Approval | 1 | 2019 | 77 | 0.660 |
Why?
| | Early Termination of Clinical Trials | 1 | 2018 | 15 | 0.650 |
Why?
| | Glucocorticoids | 3 | 2022 | 545 | 0.640 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 222 | 0.630 |
Why?
| | Sample Size | 1 | 2018 | 133 | 0.620 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 969 | 0.600 |
Why?
| | Atherosclerosis | 2 | 2017 | 345 | 0.550 |
Why?
| | Ischemia | 1 | 2018 | 374 | 0.530 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 36 | 0.530 |
Why?
| | Drugs, Investigational | 1 | 2015 | 31 | 0.530 |
Why?
| | Aspirin | 1 | 2018 | 334 | 0.520 |
Why?
| | Hospitals | 2 | 2017 | 598 | 0.510 |
Why?
| | Patient Care Planning | 1 | 2016 | 143 | 0.510 |
Why?
| | Patient Selection | 1 | 2018 | 676 | 0.480 |
Why?
| | Endovascular Procedures | 1 | 2018 | 276 | 0.480 |
Why?
| | Algorithms | 2 | 2023 | 1541 | 0.460 |
Why?
| | Insulin Resistance | 3 | 2024 | 1180 | 0.450 |
Why?
| | Swine, Miniature | 1 | 2013 | 71 | 0.450 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 306 | 0.430 |
Why?
| | Hospitalization | 2 | 2016 | 1785 | 0.370 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 394 | 0.330 |
Why?
| | Humans | 21 | 2024 | 118974 | 0.260 |
Why?
| | Insulin | 2 | 2023 | 2162 | 0.250 |
Why?
| | Heart Failure | 1 | 2016 | 1969 | 0.230 |
Why?
| | Glucose Intolerance | 1 | 2024 | 139 | 0.210 |
Why?
| | Endocrinology | 1 | 2023 | 68 | 0.210 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 75 | 0.200 |
Why?
| | Steroids | 1 | 2022 | 153 | 0.200 |
Why?
| | Obesity | 2 | 2023 | 2746 | 0.200 |
Why?
| | Treatment Outcome | 4 | 2019 | 9342 | 0.200 |
Why?
| | Dyslipidemias | 1 | 2023 | 162 | 0.200 |
Why?
| | Glucose | 2 | 2023 | 953 | 0.200 |
Why?
| | Dexamethasone | 1 | 2022 | 320 | 0.190 |
Why?
| | Prediabetic State | 1 | 2023 | 234 | 0.180 |
Why?
| | Risk Factors | 3 | 2019 | 9000 | 0.180 |
Why?
| | United States | 5 | 2023 | 12555 | 0.160 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 250 | 0.160 |
Why?
| | Hypercholesterolemia | 1 | 2017 | 93 | 0.150 |
Why?
| | Diet | 2 | 2015 | 1153 | 0.150 |
Why?
| | Electronic Health Records | 1 | 2023 | 829 | 0.140 |
Why?
| | Quality of Health Care | 1 | 2021 | 586 | 0.140 |
Why?
| | Anticholesteremic Agents | 1 | 2017 | 130 | 0.140 |
Why?
| | Male | 8 | 2021 | 57801 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 76 | 0.140 |
Why?
| | Female | 8 | 2021 | 61565 | 0.130 |
Why?
| | Nausea | 1 | 2015 | 107 | 0.130 |
Why?
| | Mexican Americans | 1 | 2015 | 100 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 3588 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 794 | 0.130 |
Why?
| | Quality of Life | 2 | 2023 | 2366 | 0.130 |
Why?
| | Hypertension | 1 | 2023 | 1203 | 0.120 |
Why?
| | Adiponectin | 1 | 2015 | 226 | 0.120 |
Why?
| | Lactic Acid | 1 | 2015 | 282 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2018 | 1687 | 0.120 |
Why?
| | Aged | 4 | 2021 | 19657 | 0.110 |
Why?
| | Insulin, Isophane | 1 | 2013 | 16 | 0.110 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2013 | 58 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 198 | 0.110 |
Why?
| | Parenteral Nutrition | 1 | 2013 | 92 | 0.110 |
Why?
| | Disease Management | 1 | 2016 | 571 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
| | Enteral Nutrition | 1 | 2013 | 170 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2013 | 218 | 0.100 |
Why?
| | Arteries | 1 | 2013 | 250 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2013 | 150 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 1945 | 0.100 |
Why?
| | Middle Aged | 4 | 2018 | 27617 | 0.100 |
Why?
| | Adiposity | 1 | 2015 | 516 | 0.100 |
Why?
| | Swine | 1 | 2013 | 730 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2021 | 2235 | 0.090 |
Why?
| | Vasodilation | 1 | 2013 | 457 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3057 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2013 | 378 | 0.090 |
Why?
| | Phosphorylation | 1 | 2013 | 1633 | 0.080 |
Why?
| | Endocrinologists | 1 | 2023 | 12 | 0.060 |
Why?
| | Disease Models, Animal | 1 | 2013 | 3730 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2023 | 89 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 368 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2024 | 233 | 0.050 |
Why?
| | Adolescent | 2 | 2015 | 18480 | 0.050 |
Why?
| | Intensive Care Units | 1 | 2023 | 635 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 310 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 502 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 534 | 0.040 |
Why?
| | Plaque, Atherosclerotic | 1 | 2017 | 40 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1720 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 2874 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2017 | 316 | 0.030 |
Why?
| | Diet Surveys | 1 | 2015 | 85 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3003 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 201 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2424 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 667 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2021 | 4596 | 0.030 |
Why?
| | Self Report | 1 | 2015 | 699 | 0.030 |
Why?
| | Animals | 1 | 2013 | 33381 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 1284 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6471 | 0.020 |
Why?
| | Colorado | 1 | 2015 | 4196 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4552 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2016 | 6561 | 0.020 |
Why?
| | Adult | 2 | 2016 | 31512 | 0.020 |
Why?
| | Young Adult | 1 | 2015 | 10793 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 12978 | 0.010 |
Why?
|
|
Low Wang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|